SCHEMBL4428745

SCHEMBL4428745

O=C1N(c2ccccc2)C(=O)C(Cc2ccccc2)(Cc2ccccc2)C(=O)N1c1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 11/20 0.74
ALDH1A1 P00352 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
THPO P40225 1/20 0.53
MAPK1 P28482 1/20 0.50
NPSR1 Q6W5P4 1/20 0.46
MGLL Q99685 1/20 0.42
GRK5 P34947 1/20 0.42
TYRO3 Q06418 1/20 0.42
DYRK1B Q9Y463 1/20 0.42
GAA P10253 1/20 0.41
F2 P00734 1/20 0.41
PLG P00747 1/20 0.41
CTSG P08311 1/20 0.41
CMA1 P23946 1/20 0.41
CTRC Q99895 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16865423 0.84 ELANE (0.58) ELANEALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL17716270 0.84 ELANE (0.87) ELANEALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL17716273 0.82 ELANE (0.89) ELANENPSR1
SCHEMBL16867613 0.80 ELANE (0.54) ELANEALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL16865407 0.80 ELANE (0.54) ELANEALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL16865396 0.79 ELANE (0.53) ELANEALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL16865424 0.79 ELANE (0.53) ELANEALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL16865418 0.77 ELANE (0.51) ELANEALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL16867647 0.77 ELANE (0.51) ELANEALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL2044288 0.77 ELANE (0.56) ELANEALDH1A1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081576-A2 METHOD OF IMPROVING BIOAVAILABILITY FOR NON-SEDATING BARBITURATES Taro Pharmaceuticals North America, Inc. (KY) 2009-07-29 EP claimed
WO-2008066704-A2 METHOD OF IMPROVING BIOAVAILABILITY FOR NON-SEDATING BARBITURATES TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) 2008-06-05 WO claimed
US-20080132529-A1 Method of improving bioavailability for non-sedating barbiturates TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-06-05 US claimed
CN-1291720-C Non-sedating barbituric acid derivatives TARO PHARMA IND (IL) 2006-12-27 CN claimed
EP-1485101-A4 NON-SEDATING BARBITURIC ACID DERIVATIVES TARO PHARMA IND (IL) 2006-04-12 EP claimed
US-6939873-B2 Non-sedating barbituric acid derivatives TARO PHARMACEUTICALS INDUSTRIES LIMITED (IL) 2005-09-06 US claimed
CN-1625401-A Non-sedating barbituric acid derivatives TARO PHARMA IND (IL) 2005-06-08 CN claimed
EP-1485101-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES Taro Pharmaceutical Industries Limited (IL) 2004-12-15 EP claimed
US-20030187005-A1 Non-sedating barbituric acid derivatives TARO PHARMACEUTICAL INDUSTRIES LTD. 2003-10-02 US claimed
WO-2003063872-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-08-07 WO claimed
EP-2081576-A2 METHOD OF IMPROVING BIOAVAILABILITY FOR NON-SEDATING BARBITURATES Taro Pharmaceuticals North America, Inc. (KY) 2009-07-29 EP disclosed
WO-2008066704-A2 METHOD OF IMPROVING BIOAVAILABILITY FOR NON-SEDATING BARBITURATES TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) 2008-06-05 WO disclosed
US-20080132529-A1 Method of improving bioavailability for non-sedating barbiturates TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-06-05 US disclosed
US-20080132529-A1 Method of improving bioavailability for non-sedating barbiturates TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-06-05 US disclosed
US-20080132529-A1 Method of improving bioavailability for non-sedating barbiturates TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-06-05 US disclosed
US-6939873-B2 Non-sedating barbituric acid derivatives TARO PHARMACEUTICALS INDUSTRIES LIMITED (IL) 2005-09-06 US disclosed
CN-1625401-A Non-sedating barbituric acid derivatives TARO PHARMA IND (IL) 2005-06-08 CN disclosed
EP-1485101-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES Taro Pharmaceutical Industries Limited (IL) 2004-12-15 EP disclosed
US-20030187005-A1 Non-sedating barbituric acid derivatives TARO PHARMACEUTICAL INDUSTRIES LTD. 2003-10-02 US disclosed
WO-2003063872-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132529-A1 Method of improving bioavailability for non-sedating barbiturates MTNR1B, GABRB3, GABBR1 ELANE 3270/4885ALDH1A1 790/4885CYP1A2 299/4885
US-20030187005-A1 Non-sedating barbituric acid derivatives GABRA5, GABRA1, GABRA3 ELANE 846/4885ALDH1A1 283/4885CYP1A2 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.